Abstract 3731
Background
The CYP1A1 gene is located on chromosome 15 (15q22-q24.1) and is part of the cytochrome P450 family. This catabolizing enzyme has an important role in the activation / deactivation of various chemical agents, including xenobiotics and sex hormones. It is related to the synthesis of cholesterol and steroids, and to the metabolism of drugs, coffee, or different metabolites such as those of tobacco. It is found mainly in extrahepatic tissues such as lung, breast or ovarian follicles, and participates in the metabolism of a large number of xenobiotics as well as one of endogenous substrates. Human cytochrome P450 1A 1 is one of the most important enzymes involved in the human carcinogenesis because it metabolizes several procarcinogens to active carcinogens. There are previous studies that have linked rs2470893 with ovarian cancer. Our aim has been to estimate the association between polymorphism rs2470893 of the CYP1A1 gene on ovarian and endometrial cancer in a Mediterranean population.
Methods
We have carried out an observational study at baseline and longitudinally in the PREDIMED-Valencia study including 696 women at high cardiovascular risk. We prospectively analyzed cancer incidence as a secondary outcome in this study. Lifestyle, clinical and biochemical variables were assessed by standardized methods. DNA was isolated from blood and the selected polymorphisms were determined
Results
We detected 8 new cases of ovarian and endometrial cancer from 2003 to 2014, representing 0.6% and 0.1% respectively, of all cancers. In our study it was observed that the variant rs2470893 was related to ovarian and endometrial cancer. The allelic frequency of the A allele was 0.246. The carriers of the G allele were grouped in front of the AA carriers. When assessing the risk of having suffered from ovarian or endometrial cancer according to the genotype of this variant, it was observed that the individuals carrying the AA allele presented a higher risk OR = 8.7: CI 95% (2.4-31.9); P = 0.001 after adjustment for age, intervention group, tobacco smoking and obesity (BMI ≥ 30 Kg/m2).
Conclusions
rs2470893of the CYP1A1 gene could be associated with ovarian and endometrial cancer in a high cardiovascular risk population.
Clinical trial identification
ISRCTN35739639.
Legal entity responsible for the study
University of Valencia.
Funding
Instituto de Salud Carlos III.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3311 - The safety and efficacy of FOLFOXIRI plus molecular target therapy as a first-line treatment for metastatic colorectal cancer: A multicentre retrospective study
Presenter: Takatsugu Ogata
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5820 - Phase II Study of Cetuximab Rechallenge in Patients with RAS Wild-Type metastatic Colorectal Cancer: E-Rechallenge Trial
Presenter: Hiroshi Osawa
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4308 - RET rearrangements may arise following anti-EGFR therapy in advanced colorectal cancer
Presenter: Thereasa Rich
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1900 - A biomarker study to validate predictors for clinical outcome of cetuximab based chemotherapy in first-line metastatic colorectal cancer (mCRC) patients: JACCRO CC-05/06AR and FIRE-3
Presenter: Yu Sunakawa
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4287 - Retrospective RAS Analysis of the EPIC Trial: Cetuximab Plus Irinotecan vs Irinotecan in Patients (pts) With Second-Line Metastatic Colorectal Cancer (mCRC)
Presenter: Alberto Sobrero
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3074 - Withholding Anti-EGFR: ImpacT on Outcome of RAS wild-type metastatic Colorectal Tumors (WAIT OR ACT): a multicentric AGEO study
Presenter: Lola-Jade Palmieri
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3440 - Prospective biomarker study in advanced RAS wild-type colorectal cancer. POSIBA trial.
Presenter: Xabier García Albéniz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2869 - Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC). A retrospective analysis of the randomized phase I/II Poseidon study.
Presenter: Rita Laeufle
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4835 - Histopathologic evaluation of patients with liver-limited metastatic colorectal cancer receiving mFOLFOX6 plus bevacizumab or mFOLFOX6 plus cetuximab: The ATOM trial.
Presenter: Yasunori Emi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5669 - Verification of guideline conform mCRC treatment with EGFR inhibitors with real-world evidence data from EU5 countries
Presenter: Laura Hoyer
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract